Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irinotecan hydrochloride liposome
- Development stage
- Unknown
- Lead developer
- Luye Pharma
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LOP002 is a liposomal formulation of irinotecan hydrochloride, a semi-synthetic derivative of camptothecin, being developed by Lee's Pharmaceutical. As a topoisomerase I inhibitor, it works by binding to the topoisomerase I-DNA complex, preventing the religation of single-strand breaks and inducing lethal double-strand DNA damage during the S-phase of the cell cycle. The liposomal encapsulation is designed to improve the therapeutic index of irinotecan by prolonging its circulation time and increasing drug accumulation within tumor tissues via the enhanced permeability and retention (EPR) effect, while potentially reducing systemic toxicities. LOP002 is primarily being investigated for the treatment of metastatic pancreatic cancer and is currently in Phase 3 clinical development in China.
- Brand names
- Duo En YiDuoenyiOnivyde
- Other names
- Irinotecan hydrochloride liposome injection
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on Irinotecan hydrochloride liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Irinotecan hydrochloride liposome.